U.S. Software Stock News

Hingham Institution for Savings (HIFS) posted net profit margins of 49.9% for the year, a marked jump from 39.6% twelve months ago, with EPS-powered earnings growing 95.4%. Despite this impressive surge, the company’s five-year record shows earnings declined by an average of 17.9% per year. Shares are trading at $272.18, representing a Price-to-Earnings ratio of 13.1x, notably above both the US Banks industry average (11.3x) and its peers (12.1x), and well over the fair value estimate of...

Trying to decide what to do with TELUS International (Cda) stock? You are not alone. This is one of those names that has people wondering if the tides are finally turning, or if caution is still the right call. After a challenging few years, TELUS International's share price has caught some positive momentum, climbing 12.0% year-to-date and up 17.3% over the past year. But let’s be real. The memory of that steep 82.3% drop over the last three years is hard to ignore for any investor who’s...

One and one Green Technologies (NasdaqCM:YDDL) recently completed its widely discussed initial public offering on the Nasdaq. The event drew attention as shares jumped sharply in both premarket and after-hours trading on debut. See our latest analysis for One and one Green Technologies. The early days of trading for One and one Green Technologies have been anything but quiet. Following its Nasdaq debut, the company’s share price surged for a 1-day share price return of 21.03%, propelled by a...

aTyr Pharma recently reported that its Phase 3 trial for efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint, leading to a wave of investor class action lawsuits alleging misleading statements about the drug’s efficacy. There is significant investor scrutiny on the company’s prior disclosures and communications, as legal investigations focus on the statements made during the trial period. We’ll examine how the trial failure and rising legal challenges may impact aTyr...

LENZ Therapeutics announced the nationwide availability of VIZZ, its FDA-approved aceclidine-based eye drop for presbyopia, with product sample distribution to eye care professionals and commercial shipments to consumers expected to begin soon. VIZZ is the first and only aceclidine-based eye drop approved by the FDA for presbyopia, featuring a unique, primarily pupil-selective mechanism of action that significantly improves near vision without causing a myopic shift. We’ll now examine how...

If you have been staring at Churchill Downs stock, weighing whether to wait out the losses or jump in for a potential rebound, you are not alone. The company has faced significant pressure this year, with shares down 31.6% year-to-date and off 35.1% over the last twelve months. That is not a typo, and it is natural to feel cautious when the recent 7-day and 30-day returns have also been negative, falling by 6.2% and 6.5% respectively. Long-term holders see only a modest 5.2% gain over five...

Accenture (ACN) reported earnings growth of 5.7% year-over-year, trailing its own 5-year average annual earnings growth of 7.4%. The company’s net profit margin dipped slightly to 11% from 11.2% a year earlier, and while revenue is forecast to rise by 5.3% per year going forward, this is below the broader US market’s 9.9% projected growth rate. For investors, the results point to a balance of predictability and quality in earnings, with the current share price of $240.94 remaining below...

loanDepot (LDI) shares have seen a mild push upwards lately, trading near $3.07 after gaining almost 2% in the past week. Investors may be eyeing recent momentum, even though the stock has experienced a tough month. See our latest analysis for loanDepot. loanDepot has seen a burst of optimism lately, but that comes after a rocky stretch, including a 1-month share price return of -28.1%. Still, the momentum in 2024 is striking, with the share price up more than 57% year-to-date and an...

Figuring out what to do with Dynex Capital stock? You are definitely not alone, and the numbers are giving investors plenty to talk about. Dynex Capital has quietly posted an impressive 23.5% gain over the last year, building on a multi-year performance that includes a near 70% jump since three years ago. After a period of steady growth, the stock has recently closed at $12.98. These gains reflect more than just company fundamentals, as investor perception towards interest rates and real...

U.S. GoldMining reported third-quarter results that changed from a net loss to a net profit. The company also showed smaller losses over the first nine months of 2025 compared to last year. These earnings have caught the eye of investors. See our latest analysis for U.S. GoldMining. Thanks to its swing from losses to profit, U.S. GoldMining has sparked a surge in investor optimism, with the share price jumping 46.5% over the past month and 80.3% in the last 90 days. The year-to-date share...

Trying to decide what to do with your DRDGOLD stock or thinking about jumping in? You are not alone. Over the past year, DRDGOLD’s price has been anything but boring, rising a stunning 179.9% over the last 12 months and delivering a massive 218.8% year-to-date. In just the last month, the stock has added another 25.6%, leaving most of the sector in the dust. Even in the last week, it edged up a solid 0.5%, showing resilience as investors weigh shifting signals in the gold market. Part of this...

Trying to figure out whether to buy, sell, or hold ALLETE? You are not alone. Plenty of investors are taking a close look at the company's recent run. ALLETE’s stock price has posted some quietly impressive gains, up 5.5% over the last month and 9.4% in the past year. That solid uptrend hints at renewed investor optimism, possibly connected to ongoing shifts in the energy sector and investor confidence in utilities. Over longer timeframes, ALLETE’s performance stands out even more, with...

Key Insights The projected fair value for Vor Biopharma is US$48.35 based on 2 Stage Free Cash Flow to Equity Current...

Key Insights Significant control over Entera Bio by individual investors implies that the general public has more power...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

There wouldn't be many who think MarineMax, Inc.'s ( NYSE:HZO ) price-to-sales (or "P/S") ratio of 0.2x is worth a...

It is hard to get excited after looking at Louisiana-Pacific's (NYSE:LPX) recent performance, when its stock has...

Key Insights Significant control over RCI Hospitality Holdings by retail investors implies that the general public has...

Standard Motor Products (NYSE:SMP) has had a great run on the share market with its stock up by a significant 16% over...

Key Insights The projected fair value for Ultra Clean Holdings is US$29.33 based on 2 Stage Free Cash Flow to Equity...

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...

Key Insights Inspired Entertainment's estimated fair value is US$11.15 based on 2 Stage Free Cash Flow to Equity...

While Willis Lease Finance Corporation ( NASDAQ:WLFC ) might not have the largest market cap around , it saw...

Viomi Technology (NASDAQ:VIOT) has had a rough week with its share price down 16%. We, however decided to study the...